ArticleACS omega2026
Multimodal Mechanism of Antitumoral Ni(II) Thiosemicarbazones: Deep Mechanistic Understanding of ROS Dynamics, Albumin-Mediated Delivery, and DNA Targeting.
Article in ACS omega, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer accounts for nearly one in four deaths (22.8%) due to noncommunicable diseases globally. The urgency for new effective therapies is worsened by resistance. One strategy is to look for multimodal drugs, which undergo different pathways to achieve selective cytotoxicity. Thiosemicarbazones are known to act as antitumoral compounds through multiple modes of action, and Ni-(II) shares some coordination properties with Pt-(II) but is also accessible to redox reactions such as superoxide dismutation catalysis. We found that, in a list of four thiosemicarbazone Ni-(II) complexes all tested on various cancer cell lines,
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.